T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent increase from 2023, according to a Globe analysis of insurance claims data.

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

Since weight-loss drugs that target the hormone GLP-1 have surged in popularity, some additional health benefits have emerged. Beyond helping people shed pounds, they also lower the risk of heart disease and sleep apnea—and the U.

In the first clinical trial of its kind, people taking semaglutide drank less alcohol, adding to its promise of fighting addiction.